Metronomic chemotherapy dosing-schedules with estramustine and temozolomide act synergistically with anti-VEGFR-2 antibody to cause inhibition of human umbilical venous endothelial cell growth

Acta Oncologica

Volumn 46, Issue 8, 2007, Pages 1169-1177

  Lam, Thomas ^a,b   Hetherington, John W ^b   Greenman, John ^a   Little, Samantha ^a,b   Maraveyas, Anthony ^a,c  

^a UNIVERSITY OF HULL   (United Kingdom)

^b CASTLE HILL HOSPITAL   (United Kingdom)

^c PRINCESS ROYAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COMPOUND 5H; ESTRAMUSTINE; ESTRAMUSTINE PHOSPHATE; MONOCLONAL ANTIBODY IMC 1C11; PACLITAXEL; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSE REGIMEN; ENDOTHELIUM CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PRIORITY JOURNAL;

ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL PROLIFERATION; CELLS, CULTURED; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; ENDOTHELIAL CELLS; ESTRAMUSTINE; HUMANS; PACLITAXEL; TIME FACTORS; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 35848951884     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860701373603     Document Type: Article

References (29)

1. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: 'Metronomic' dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-7.
2. Kerbel RS, Kamen BA. The anti-angiogenic basis of 'metronomic' chemotherapy. Nature Rev Cancer 2004;4:423-6.
3. du Manoir JM, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A, et al. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 2006;12:904-16.
4. Yap R, Veliceasa D, Emmenegger U, Kerbel RS, McKay LM, Henkin J, et al. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: A complementation antiangiogenic strategy. Clin Cancer Res 2005;11:6678-85.
5. Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, et al. High-dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res 2006;12:5190-8.
6. Orlando L, Cardillo A, Ghisini R, Rocca A, Balduzzi A, Torrisi R, et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 2006;15:225-35.
7. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002;62:6938-43.
8. Wang J, Lou P, Lesniewski R, Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 2003;14:13-9.
9. Posey JA, Ng TC, Yang B, Khazaeli MB, Carpenter MD, Fox F, et al. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 2003;9:1323-32.
10. Bell IM, Gallicchio SN, Abrams M, Beshore DC, Buser CA, Culberson JC, et al. Design and biological activity of (S)-4-(5-([1-(3-chlorobenzyl)-2- oxopyrrolidin-3-ylamino] methyl)imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrroli-dinone farnesyltransferase inhibitor with excellent cell potency. J Med Chem 2001;44:2933-49.
11. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-24.
12. Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P, et al. Differences in therapeutic indexes of combination 'metronomic' chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 2002;8:221-32.
13. Han JY, Oh SH, Morgillo F, Myers JN, Kim E, Hong WK, et al. Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst 2005;97:1272-86.
14. Johns TG, Luwor RB, Murone C, Walker F, Weinstock J, Vitali AA, et al. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Proc Natl Acad Sci USA 2003;100:15871-6.
15. Webb JL. Enzyme and metabolic inhibitors. New York: Academic Press; 1963. p. 150-3.
16. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin-1, a mediator of the anti-angiogenic effects of low dose metronomic chemotherapy. Proc Natl Acad Sci USA 2003;100:12917-22.
17. Gunnarsson PO, Andersson SB, Johansson SA, Nilsson T, Plym-Forshell G. Pharmacokinetics of estramustine phosphate (Estracyt) in prostatic cancer patients. Eur J Clin Pharmacol 1984;26:113-9.
18. Hudes G, Haas N, Yeslow G, Gillon T, Gunnarsson PO, Ellman M, et al. Phase I clinical and pharmacologic trial of intravenous estramustine phosphate. J Clin Oncol 2002;20:1115-27.
19. Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC, et al. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 1997;3:1093-100.
20. Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998;58:4363-7.
21. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG. Taxol: The first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992;19:646-62.
22. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, et al. Anti-angiogenic scheduling of chemotherapy improves efficacy against experimental drugresistant cancer. Cancer Res 2000;60:1878-86.
23. Funovics P, Brostjan C, Nigisch A, Fila A, Grochot A, Mleczko K, et al. Effects of 15d-PGJ(2) on VEGF-induced angiogenic activities and expression of VEGF receptors in endothelial cells. Prostaglandins Other Lipid Mediat 2006;79:230-44.
24. Nimi Y, Mochida S, Matsui A, Inao M, Fujiwara K. PKC- and MAPK-independent upregulation of VEGF receptor expressions in human umbilical venous endothelial cells following VEGF stimulation. Hepatol Res 2001;21:261-7.
25. Morqillo F, Lee HY. Lonafarnib in cancer therapy. Expert Opin Investig Drugs 2006;15:709-19.
26. Satoh T, Endo M, Nakafuku M, Akiyama T, Yamamoto T, Kaziro. Accumulation of p21ras.GTP in response to stimulation with epidermal growth factor and oncogene products with tyrosine kinase activity. Proc Natl Acad Sci USA 1990;87:7926-9.
27. Gu WZ, Joseph I, Wang YC, Frost D, Sullivan GM, Wang L, et al. A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies. Anticancer Drugs 2005;16:1059-69.
28. Oh SH, Kim WY, Kim JH, Younes MN, El-Naggar AK, Myers JN, et al. Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma. Clin Cancer Res 2006;12:653-61.
29. Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR. American Society of Clinical Oncology Technology Assessment: Chemotherapy sensitivity and resistance assays. J Clin Oncol 2004;22:3631-8.